Loading clinical trials...
Loading clinical trials...
The IMAGINE Study: A Phase 3b Open Label, Single Arm Study to Assess the Effect of Depemokimab on Airway Structure and Function in Asthma With Type 2 Inflammation Characterized by an Eosinophilic Phenotype Utilizing Quantitative High-resolution CT and Bronchoscopic Airway Sampling in a Sub Study
Conditions
Interventions
Depemokimab
Locations
43
United States
GSK Investigational Site
Brooksville, Florida, United States
GSK Investigational Site
Plantation, Florida, United States
GSK Investigational Site
Kansas City, Kansas, United States
GSK Investigational Site
St Louis, Missouri, United States
GSK Investigational Site
New Brunswick, New Jersey, United States
GSK Investigational Site
New York, New York, United States
Start Date
June 3, 2025
Primary Completion Date
December 8, 2027
Completion Date
February 11, 2028
Last Updated
April 23, 2026
NCT07431021
NCT07383896
NCT07282886
NCT07356310
NCT06003569
NCT05562466
Lead Sponsor
GlaxoSmithKline
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions